

S/N 10/722,292

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SHIMKETS ET AL.	Examiner:	S. SAKELARIS
Serial No.:	10/722,292	Group Art Unit:	1634
Filed:	NOVEMBER 25, 2003	Docket No.:	11669.206USDI
Confirmation No.:	9115	Customer No.:	23552
Title:	METHOD OF DETECTING CARDIAC HYPERTROPHY THROUGH PROBE HYBRIDIZATION AND GENE EXPRESSION ANALYSIS		

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

Certification Under 37 C.F.R. §1.97(e)(1)

In accordance with 37 C.F.R. §1.97(c) or §1.97(d), the undersigned hereby certifies that each item of information listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart foreign application within three months of filing this statement.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: September 8, 2006 Katherine M. Kowalchyk
Katherine M. Kowalchyk
Reg. No. 36,848



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>			Docket Number: 11669.206US1	Application Number: 10/722,292
			Applicant: SHIMKETS ET AL.	
			Filing Date: 11/25/2003	Group Art Unit: 1634

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2003/0148296 A1	08/07/2003	Brown et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	WO 92/12238	07/23/1992	PCT			
	WO 97/16209	05/09/1997	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Cooper, "Basic Determinants of Myocardial Hypertrophy: A Review of Molecular Mechanisms", <i>Annu. Rev. Med.</i> , 48:13-23 (1997)					
	Hannan et al., "Cardiac Hypertrophy: A Matter of Translation", <i>Clinical and Experimental Pharmacology and Physiology</i> , 30:517-527 (2003)					
	McGill et al., "Cell cycle control mechanisms and their role in cardiac growth", <i>Cardiovascular Research</i> , 30:557-569 (1995)					
	Ritter et al., "The molecular basis of myocardial hypertrophy and heart failure", <i>TRENDS in Molecular Medicine</i> , 9(7):313-321 (2003)					
	Sadoshima et al., "Angiotensin II and Serum Differentially Regulate Expression of Cyclins, Activity of Cyclin-Dependent Kinases, and Phosphorylation of Retinoblastoma Gene Product in Neonatal Cardiac Myocytes", <i>Circulation Research</i> , 80:228-241 (1997)					
	Copy of European Search Report dated June 19, 2006					

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	